FDA approves landmark pancreatic cancer drug that’s shown to improve survival - AP News

FDA approves landmark pancreatic cancer drug that’s shown to improve survival  AP News

F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

By Gina Kolata and Rebecca Robbins

FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease - WSJ

FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease  WSJ

FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.

By Daniel Wu

FDA gives expedited approval to new groundbreaking pancreatic cancer drug

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pan...

By Associated Press

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug  CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. - Barron's

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.  Barron's

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time

Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.

By Mary Whitfill Roeloffs, Forbes Staff

FDA approves landmark pancreatic cancer drug that's shown to improve survival

Revolution Medicines gets FDA approval for targeted pancreatic cancer drug

The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

Revolution Medicines nabs approval of pancreatic cancer therapy daraxonrasib

FDA approves groundbreaking pancreatic cancer drug

FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - Taiwan News

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer  Taiwan News

U.S. FDA approves landmark pancreatic cancer drug that’s shown to improve survival

The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.

By Deborah Okailey Quarcoo